A planar amperometric creatinine biosensor employing an insoluble oxidizing agent for removing redox-active interferences

Electrochemical Creatinine (Bio)Sensors for Point-of-Care Diagnosis of Renal Malfunction and Chronic Kidney Disorders

In the post-pandemic era, point-of-care (POC) diagnosis of diseases is an important research frontier. Modern portable electrochemical (bio)sensors enable the design of POC diagnostics for the identification of diseases and regular healthcare monitoring. Herein, we present a critical review of the electrochemical creatinine (bio)sensors. These sensors either make use of biological receptors such as enzymes or employ synthetic responsive materials, which provide a sensitive interface for creatinine-specific interactions. The characteristics of different receptors and electrochemical devices are discussed, along with their limitations. The major challenges in the development of affordable and deliverable creatinine diagnostics and the drawbacks of enzymatic and enzymeless electrochemical biosensors are elaborated, especially considering their analytical performance parameters. These revolutionary devices have potential biomedical applications ranging from early POC diagnosis of chronic kidney disease (CKD) and other kidney-related illnesses to routine monitoring of creatinine in elderly and at-risk humans.

High stability resistive switching mechanism of a screen-printed electrode based on BOBZBT2 organic pentamer for creatinine detection

The resistive switching (RS) mechanism is resulted from the formation and dissolution of a conductive filament due to the electrochemical redox-reactions and can be identified with a pinched hysteresis loop on the I-V characteristic curve. In this work, the RS behaviour was demonstrated using a screen-printed electrode (SPE) and was utilized for creatinine sensing application. The working electrode (WE) of the SPE has been modified with a novel small organic molecule, 1,4-bis[2-(5-thiophene-2-yl)-1-benzothiopene]-2,5-dioctyloxybenzene (BOBzBT2). Its stability at room temperature and the presence of thiophene monomers were exploited to facilitate the cation transport and thus, affecting the high resistive state (HRS) and low resistive state (LRS) of the electrochemical cell. The sensor works based on the interference imposed by the interaction between the creatinine molecule and the radical cation of BOBzBT2 to the conductive filament during the Cyclic Voltammetry (CV) measurement. Different concentrations of BOBzBT2 dilution were evaluated using various concentrations of non-clinical creatinine samples to identify the optimised setup of the sensor. Enhanced sensitivity of the sensor was observed at a high concentration of BOBzBT2 over creatinine concentration between 0.4 and 1.6 mg dL-1-corresponding to the normal range of a healthy individual.

A nano-integrated microfluidic biochip for enzyme-based point-of-care detection of creatinine

A nano-integrated portable enzymatic microfluidic electrochemical biochip was developed for single-step point-of-care testing of creatinine. The biochip could automatically eliminate a lot of interferences from practical biological samples and enzymatic intermediate products. Gold nanostructure- and carbon nanotube-based screen-printed carbon electrodes were integrated into microfluidic structures to improve the detection performance for creatinine. The microfluidic electrochemical biochip holds promise to become a practical device for medical diagnosis, especially POCT.

Advances in the Detection, Mechanism and Therapy of Chronic Kidney Disease

Chronic Kidney Disease (CKD) is characterized by the gradual loss of renal mass and functions. It has become a global health problem, with hundreds of millions of people being affected. Both its incidence and prevalence are increasing over time. More than $20,000 are spent on each patient per year. The economic burden on the patients, as well as the society, is heavy and their life quality worsen over time. However, there are still limited effective therapeutic strategies for CKD. Patients mainly rely on dialysis and renal transplantation, which cannot prevent all the complications of CKD. Great efforts are needed in understanding the nature of CKD progression as well as developing effective therapeutic methods, including pharmacological agents. This paper reviews three aspects in the research of CKD that may show great interests to those who devote to bioanalysis, biomedicine and drug development, including important endogenous biomarkers quantification, mechanisms underlying CKD progression and current status of CKD therapy.

Sensitive Detection of Serum Creatinine Based on β-Cyclodextrin-Ferrocenylmethanol Modified Screen-printed Electrode

Ferrocenylmethanol (Fc-OH) is included in β-cyclodextrin (β-CD) to form the β-CD-Fc-OH complex by host-guest supramolecular interaction. β-CD dissociates from the β-CD-Fc-OH complex due to the conversion of Fc-OH to Fc⁺-OH under a stimulus of oxidant. In our study, Fc-OH is oxidized after a series of enzymatic reactions of creatinine, which blocks the other means for oxidation of Fc-OH. And the background noise is reduced for testing for serum creatinine (sCr). The chronoamperometry signal for creatinine (with a constant potential -0.3 V vs. Ag/AgCl) increases linearly in the 1 - 1000 μM range, with a limit of detection as low as 0.5 μM. The amperometric potential of -0.3 V greatly prevents the interference of various redox substances in serum. The biosensor was used to test 120 clinical specimens and the results showed a linear correlation with the biochemical analyzer (R² = 0.9885). The biosensor could be applied to clinical trials and offers good prospects for clinical sCr detection.

Biosensing methods for determination of creatinine: A review

Creatinine is a metabolic product of creatine phosphate in muscles, which provides energy to muscle tissues. Creatinine has been considered as indicator of renal function specifically after dialysis, thyroid malfunction and muscle damage. The normal level of creatinine in the serum and its excretion through urine in apparently healthy individuals is 45-140 μM and 0.8-2.0 gm/day respectively. The level of creatinine reaches >1000 μM in serum during renal, thyroid and kidney dysfunction or muscle disorder. A number of conventional methods such as colorimetric, spectrophotometric and chromatographic are available for determination of creatinine. Besides the advantages of being highly sensitive and selective, these methods have some drawbacks like time-consuming, requirement of sample pre-treatment, high cost instrumental set-up and skilled persons to operate. The sensors/biosensors overcome these drawbacks, as these are fast, easy, cost effective and highly sensitive. This review article describes the classification, operating principles, merits and demerits of various creatinine sensors/biosensors, specifically nanomaterials based biosensors. Creatinine biosensors work optimally within 2-900 s, potential range 0.1-1.0 V, pH range 4.0-10.0, temperature range 25-35 °C and had linear range, 0.004-30000 µM for creatinine with the detection limit between 0.01.01 µM and 520 µM. These biosensors measured creatinine level in sera and urine samples and had storage stability between 4 and 390 days, while being stored dry at 4 °C. The future perspective for further improvement and commercialization of creatinine biosensors are discussed.

A new disposable microfluidic electrochemical paper-based device for the simultaneous determination of clinical biomarkers

A new disposable microfluidic electrochemical paper-based device (ePAD) consisting of two spot sensors in the same working electrode for the simultaneous determination of uric acid and creatinine was developed. The spot 1 surface was modified with graphene quantum dots for direct uric acid oxidation and spot 2 surface modified with graphene quantum dots, creatininase and a ruthenium electrochemical mediator for creatinine oxidation. The ePAD was employed to construct an electrochemical sensor (based on square wave voltammetry analysis) for the simultaneous determination of uric acid and creatinine in the 0.010-3.0 µmol L^-1 range. The device showed excellent analytical performance with a very low simultaneous detection limit of 8.4 nmol L^-1 to uric acid and 3.7 nmol L^-1 to creatinine and high selectivity. The ePAD was applied to the rapid and successful determination of those clinical biomarkers in human urine samples.

Creasensor: SIMPLE technology for creatinine detection in plasma

The lab-on-a-chip (LOC) field has witnessed an excess of new technology concepts, especially for the point-of-care (POC) applications. However, only few concepts reached the POC market often because of challenging integration with pumping and detection systems as well as with complex biological assays. Recently, a new technology termed SIMPLE was introduced as a promising POC platform due to its features of being self-powered, autonomous in liquid manipulations, cost-effective and amenable to mass production. In this paper, we improved the SIMPLE design and fabrication and demonstrated for the first time that the SIMPLE platform can be successfully integrated with biological assays by quantifying creatinine, biomarker for chronic kidney disease, in plasma samples. To validate the robustness of the SIMPLE technology, we integrated a SIMPLE-based microfluidic cartridge with colorimetric read-out system into the benchtop Creasensor. This allowed us to perform on-field validation of the Creasensor in a single-blind study with 16 plasma samples, showing excellent agreement between measured and spiked creatinine concentrations (ICC: 0.97). Moreover, the range of clinically relevant concentrations (0.76-20 mg/dL), the sample volume (5 μL) and time-to-result of only 5 min matched the Creasensor performance with both lab based and POC benchmark technologies. This study demonstrated for the first time outstanding robustness of the SIMPLE in supporting the implementation of biological assays. The SIMPLE flexibility in liquid manipulation and compatibility with different sample matrices opens up numerous opportunities for implementing more complex assays and expanding its POC applications portfolio.

Picric acid capped silver nanoparticles as a probe for colorimetric sensing of creatinine in human blood and cerebrospinal fluid samples

A new approach has been proposed for the traditional Jaffe's reaction by coating Ag NPs with picric acid to form an assembly that can selectively detect creatinine. This sensor proficiently and selectively recognizes creatinine due to the ability of picric acid to bind with it and form a complex.

Novel electrochemical sensing platform based on magnetic field-induced self-assembly of Fe3O4@Polyaniline nanoparticles for clinical detection of creatinine

A novel electrochemical sensing platform based on magnetic field-induced self-assembly of Fe3O4@Polyaniline nanoparticles (Fe3O4@PANI NPs) has been for the first time fabricated for the sensitive detection of creatinine in biological fluids. The template molecule, creatinine, was self-assembled on the surface of Fe3O4@PANI NPs together with the functional monomer aniline by the formation of N-H hydrogen bonds. After pre-assembled, through the magnetic-induction of the magnetic glassy carbon electrode (MGCE), the ordered structure of molecularly imprinted polymers (MIPs) were established by the electropolymerization and assembled on the surface of MGCE with the help of magnetic fields by a simple one-step approach. The structural controllability of the MIPs film established by magnetic field-induced self-assembly was further studied. The stable and hydrophilic Fe3O4@PANI can not only provide available functionalized sites with which the template molecule creatinine can form hydrogen bond by the abundant amino groups in PANI matrix, but also afford a promoting pathway for electron transfer. The as-prepared molecularly imprinted electrochemical sensor (MIES) shows good stability and reproducibility for the determination of creatinine with the detection limit reached 0.35 nmol L(-1) (S/N=3). In addition, the highly sensitive and selective MIES has been successfully used for the clinical determination of creatinine in human plasma and urine samples. The average recoveries were 90.8-104.9% with RSD lower than 2.7%.

Blood‐Glucose Biosensors, Development and Challenges

Diabetes mellitus is one of the major causes of premature illness and death worldwide. The World Health Organization estimated that by 2030, 439 million people, corresponding to 7.8% of the world adult population, will live with diabetes. With an increasing diabetic population, a Blood Glucose Monitoring System (BGMS) is becoming an ever important tool for diabetes management. The history of blood biosensor development can be traced back to 1932, when Warburg and Christian reported the “yellow enzyme” from yeast changed to colorless upon oxidizing its substrate and resumed the yellow color after its oxidation by oxygen. Since then a lot of research and development has taken place on blood glucose sensors, and the biosensor technology has gone through three generations, with the current commercially available BGMS predominantly relies on the second generation of technology. The advantages and challenges of each generation are discussed. This chapter will examine in detail topics covering the areas of electrode substrate and electrode material selection, fluid detection electrode, reaction chamber, chemistry (electrolyte, polymer, enzyme and mediator), detection method, analytical performance, regulatory requirements and the manufacturing process. The chapter will close with the clinical utility and future direction and application of glucose biosensor include a brief introduction to the Continuous Blood Glucose Monitoring System (CGMS).

Determination of Creatine in Commercial Creatine Powder with New Potentiometric and Amperometric Biosensors

New potentiometric and amperometric biosensors were developed for the determination of creatine. The potentiometric creatine biosensor was prepared by immobilizing urease and creatinase on poly(vinylchloride) (PVC) ammonium membrane electrode containing palmitic acid prepared by using nonactine as an ammonium-ionophore. The linear working range of the biosensor was 1.0 x 10(-5) - 1.0 x 10(-3) M and the response time was about 60 s. The optimum pH, temperature, and buffer concentration were found to be 7.0, 20 degrees C, and 5 mM, respectively. The slope of the electrode was 49.2 mV/p[creatine]. The storage stabilization of the biosensor was investigated and 40-45% decrease in the response was detected after 2 months. The amperometric creatine biosensor was prepared by immobilizing creatinase (CI) and sarcosine oxidase (SO) in a poly(vinylferrocenium) matrix onto the surface of a platinum working electrode by crosslinking with glutaraldehyde (GA) and bovine serum albumine (BSA). Determination of creatine was performed by the oxidation of enzymatically generated H2O2 at +0.7 V vs. Ag/AgCl. The linear working range of the biosensor was 2.0 x 10(-5) - 3.2 x 10(-4) M and the response time was about 50 s. The effects of pH, temperature, enzyme ratio and buffer concentration were investigated and optimum parameters were found to be 7.5, 37 degrees C, 2.5:1 (CI:SO) and 0.05 M, respectively. The determination of creatine in commercial creatine powder was successfully carried out with these creatine biosensors by using the standard addition and calibration curve methods. The results were in good agreement with those obtained from Jaffé method at 95% confidence level.

An Amperometric Enzyme Electrode for Creatine Determination Prepared by the Immobilization of Creatinase and Sarcosine Oxidase in Poly(vinylferrocenium)

A new enzyme electrode for the determination of creatine was developed by immobilizing creatinase (CI) and sarcosine oxidase (SO). The enzymes were co-immobilized in a poly(vinylferrocenium) matrix onto the surface of a platinum working electrode. Crosslinking with glutaraldehyte (GA) and bovine serum albumin (BSA) was selected as the best immobilization method for the enzymatic system. Determination of creatine was performed by the oxidation of enzymatically generated H2O2 at + 0.7 V vs. Ag/AgCl. The linear working range of the electrode was 2.0 x 10(-5) - 3.2 x 10(-4) M and the response time was about 50 s. The effects of pH, temperature, enzyme ratio and buffer concentration were investigated and optimum parameters were found to be 7.5, 37 degrees C, 2.5:1 (CI:SO) and 0.05 M, respectively. The stability and reproducibility of the enzyme electrode have been also studied.

Amperometric biosensor for the determination of creatine

An amperometric biosensor for the determination of creatine was developed. The carbon rod electrode surface was coated with sarcosine oxidase (SOX) and creatine amidinohydrolase by cross-linking under glutaraldehyde vapour. The SOX from Arthrobacter sp. 1-1 N was purified and previously used for creation of a creatine biosensor. The natural SOX electron acceptor, oxygen, was replaced by an [Fe(CN)(6)](3-) /[ Fe(CN)(6)](4-) redox mediating system, which allowed amperometric detection of an analytical signal at +400-mV potential. The response time of the biosensor was less than 1 min. The biosensor showed a linear dependence of the signal vs. creatine concentration at physiological creatine concentration levels. The optimal pH in 0.1 M tris(hydroxymethyl)aminomethane (Tris)-HCl buffer was found to be at pH 8.0. The half-life of the biosensor was 8 days in 0.1 M Tris-HCl buffer (pH 8.0) at 20 degrees C. Principal scheme of consecutively followed catalytic reactions used to design a biosensor for the determination of creatine.

Simultaneous Detection of Creatine and Creatinine using a Sequential Injection Analysis/Biosensor System

Carbon paste based biosensors for the determination of creatine and creatinine have been integrated into a sequential injection system. Applying the multi-enzyme sequence of creatininase (CA), and/or creatinase (CI) and sarcosine oxidase (SO), hydrogen peroxide has been detected amperometrically. The linear concentration ranges are of pmol/L to nmol/L magnitude, with very low limits of detection. The proposed SIA system can be utilized reliably for the on-line simultaneous detection of creatine and creatinine in pharmaceutical products, as well as in serum samples, with a rate of 34 samples per hour and RSD values better than 0.16% (n=10).

Preparation of poly(thionine) modified screen-printed carbon electrode and its application to determine NADH in flow injection analysis system

A poly(thionine) modified screen-printed carbon electrode has been prepared by an electrooxidative polymerization of thionine in neutral phosphate buffer. The modified electrodes are found to give stable and reproducible electrocatlytic responses to NADH and exhibit good stability. Several techniques, including cyclic voltammetry, X-ray photoelectron spectroscopy (XPS) and scanning electron microscopy (SEM), have been employed to characterize the poly(thionine) film. Further, the modified screen-printed carbon electrode was found to be promising as an amperometric detector for the flow injection analysis (FIA) of NADH, typically with a dynamic range of 5-100 microM.

Biosensors in clinical chemistry

Biosensors are analytical devices composed of a recognition element of biological origin and a physico-chemical transducer. The biological element is capable of sensing the presence, activity or concentration of a chemical analyte in solution. The sensing takes place either as a binding event or a biocatalytical event. These interactions produce a measurable change in a solution property, which the transducer converts into a quantifiable electrical signal. Present-day applications of biosensors to clinical chemistry are reviewed, including basic and applied research, commercial applications and fabrication techniques. Recognition elements include enzymes as biocatalytic recognition elements and immunoagents and DNA segments as affinity ligand recognition elements, coupled to electrochemical and optical modes of transduction. The future will include biosensors based on synthetic recognition elements to allow broad applicability to different classes of analytes and modes of transduction extending lower limits of sensitivity. Microfabrication will permit biosensors to be constructed as arrays and incorporated into lab-on-a-chip devices.